Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alzheimer's & Dementia

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2013.12.005PMID 24529524
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathogenesis of Parkinson's disease

  2013cited by this paper
• A Critical Analysis of the Clinical Use of Incretin-Based Therapies

  2013cited by this paper
• Parkinson's disease, insulin resistance and novel agents of neuroprotection.

  2013cited by this paper
• Exenatide and the treatment of patients with Parkinson's disease.

  2013cited by this paper
• Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

  2013cited by this paper
• A Critical Analysis of the Clinical Use of Incretin-Based Therapies

  2013cited by this paper
• Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

  2012cited by this paper
• Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.

  2012cited by this paper
• A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

  2012cited by this paper
• Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.

  2012cited by this paper
• Synaptic vesicle trafficking and Parkinson's disease

  2012cited by this paper
• Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

  2012cited by this paper
• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

  2012cited by this paper
• Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scores

  2012cited by this paper
• Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease

  2011cited by this paper
• A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease

  2011cited by this paper
• Pathological roles of α-synuclein in neurological disorders.

  2011cited by this paper
• Use of ibuprofen and risk of Parkinson disease

  2011cited by this paper
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study

  2010cited by this paper
• Rasagiline, Parkinson neuroprotection, and delayed-start trials

  2010cited by this paper
• Neurotrophic factor therapy for Parkinson's disease.

  2010cited by this paper
• The delayed-start study in Parkinson disease: Can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?

  2010cited by this paper
• Exendin‐4 protects pancreatic beta cells from human islet amyloid polypeptide‐induced cell damage: potential involvement of AKT and mitochondria biogenesis

  2010cited by this paper
• Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.

  2010cited by this paper
• Neuroinflammation in Parkinson’s Disease

  2009cited by this paper
• GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

  2009influential reference
• Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

  2009cited by this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.

  2009cited by this paper
• Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice

  2009cited by this paper
• Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

  2008cited by this paper
• Why have we failed to achieve neuroprotection in Parkinson's disease?

  2008cited by this paper
• A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

  2008cited by this paper
• Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

  2008cited by this paper
• Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?

  2008cited by this paper
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

  2008cited by this paper
• Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice

  2007cited by this paper
• Randomized Controlled Trial of Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Infusion in Parkinson Disease

  2007cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006influential reference
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

  2006cited by this paper
• Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.

  2005cited by this paper
• A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

  2005cited by this paper
• Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations

  2004cited by this paper
• A new Alzheimer's disease interventive strategy: GLP-1.

  2004cited by this paper
• Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

  2004cited by this paper
• The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

  2004cited by this paper
• Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

  2003cited by this paper
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Entry of exendin-4 into brain is rapid but may be limited at high doses

  2003cited by this paper
• Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

  2003cited by this paper
• Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

  2003cited by this paper
• Learning from the gut

  2003cited by this paper
• A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

  2002cited by this paper
• Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

  2002cited by this paper
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

  2002cited by this paper
• Neurodegeneration: a failure of neuroregeneration?

  2001cited by this paper
• Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains

  2001cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease.

  1999cited by this paper
• Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

  1994cited by this paper
• The next steps

  1993cited by this paper
• Pathogenesis of Parkinson's disease.

  1992cited by this paper
• DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

  1989cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper

• Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists.

  2026cites this paper
• Drug discovery and development for Parkinson’s disease: are preclinical models good enough?

  2025cites this paper
• Disease-Modifying Therapies in Parkinson's Disease.

  2025cites this paper
• Targeting glucose transporters in parkinson’s disease: a novel metabolic approach for disease modification

  2025cites this paper
• GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis

  2025cites this paper
• Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis

  2025cites this paper
• Epigenetic mechanisms linking environmental exposure to Parkinson's disease: A comprehensive review.

  2025cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets

  2024cites this paper
• How Lifetime Evolution of Parkinson’s Disease Could Shape Clinical Trial Design: A Shared Patient–Clinician Viewpoint

  2024cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms.

  2023cites this paper
• Fountain of youth—Targeting autophagy in aging

  2023cites this paper
• ReviewEmerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A

  2022cites this paper
• Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review

  2022cites this paper
• Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

  2022cites this paper
• Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases

  2022cites this paper
• GLP-1a: Going beyond Traditional Use

  2022cites this paper
• Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease

  2021cites this paper
• New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

  2021cites this paper
• Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity

  2021cites this paper
• Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?

  2020cites this paper
• Recent advances in understanding the role of glucagon-like peptide 1

  2020cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Animal venom peptides as a treasure trove for new therapeutics against neurodegenerative disorders.

  2019cites this paper
• The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity

  2018cites this paper
• Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

  2018cites this paper
• Hormones of energy homeostasis : linking weight loss and cognition in Parkinson's disease?

  2018cites this paper
• GLP-1 receptor agonists for Parkinson's disease.

  2018cites this paper
• Neuroprotective Effects of Eexenatide in a Rotenone‐Induced Rat Model of Parkinson's Disease☆

  2017cites this paper
• Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance.

  2017cites this paper
• Glucagon‐like receptor 1 agonists and DPP‐4 inhibitors: Anti‐diabetic drugs with anti‐stroke potential

  2017cites this paper
• A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis

  2017influential citation
• Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.

  2017cites this paper
• Microglial phenotypes in Parkinson's disease and animal models of the disease.

  2017cites this paper
• Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

  2017cites this paper
• D‐Ala2‐GIP‐glu‐PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation

  2017cites this paper
• The best medicine? The influence of physical activity and inactivity on Parkinson's disease

  2016cites this paper
• Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease

  2016cites this paper
• Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases

  2015cites this paper
• The ongoing pursuit of neuroprotection in Parkinson ’ s disease

  2015cites this paper
• Why do we study animal toxins?

  2015cites this paper
• Targeting α-synuclein as a therapeutic strategy for Parkinson’s disease

  2015cites this paper
• Neurophysiological and Behavioural Variables in Cognitive Impairment: Towards a Personalised Monitoring System

  2015cites this paper
• The ongoing pursuit of neuroprotective therapies in Parkinson disease

  2015cites this paper
• Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease

  2015cites this paper
• Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes.

  2015cites this paper
• FACULTAD DE FARMACIA UNIVERSIDAD COMPLUTENSE

  2015cites this paper
• The incretin hormones glucagonlike peptide 1 and glucose‐dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease

  2014cites this paper
• Regenerative Drugs for Parkinson's Disease

  2014cites this paper
• Is Exenatide the Next Big Thing in Parkinson's Disease?

  2014cites this paper